Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aqilion Resumes Development of its TAK1-Program
Details : Aqilion resumes TAK1 program for inflammation after regaining rights. targeting chronic inflammation such as autoimmune diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Merck Group
Deal Size : $1,025.0 million
Deal Type : Collaboration
Aqilion Announces Pre-Clinical Licensing and Strategic Research Collaboration Agreement with Merck
Details : Under the terms of the collaboration, Aqilion will be responsible for the design and synthesis of novel small molecule TAK1 inhibitors while Merck will lead preclinical pharmacology and biology studies.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : $10.6 million
February 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Merck Group
Deal Size : $1,025.0 million
Deal Type : Collaboration
Reset All
